New hope for kids with MS: ublituximab trial launches
NCT ID NCT07220252
First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 33 times
Summary
This study tests an investigational drug, ublituximab, in children and teens (ages 10-17) with relapsing multiple sclerosis (RMS). The goal is to see if it works better than the current drug fingolimod at reducing relapses, while also checking its safety and how the body processes it. About 240 participants will be followed for up to several years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.